Recommended

New webinar: Overcoming critical challenges in AI-driven drug discovery
Watch on demand: Rapid cell-based profiling of multi-target anti-obesity drugs Watch here!
Download now: Unlock the power of stem cell therapy and discover the potential for new therapies for primary open-angle glaucoma
Brand new Beyond the Lab report on antibodies… Download NOW!
article

COVID-19 In-Depth Focus 2020

Posted: 27 November 2020 | | No comments yet

This in-depth focus features articles on neuropilin-1, a potential new target for COVID-19 drug development, the creation of a lung model to enhance our understanding of SARS-CoV-2 infections and using proteomics to uncover the mechanisms behind COVID-19 symptom severity.

IDF - COVID-19

    To read this in-depth focus in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Olink Proteomics BV

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Find in this in-depth focus:

    • Neuropilin-1: a key receptor in SARS-CoV-2 infection
      Results of a recent study by researchers at the University of Bristol indicate neuropilin-1 is an important host factor for SARS-CoV-2 infection. The team suggests that blocking neuropilin-1 may be a valuable therapeutic intervention in the treatment of COVID-19. Nikki Withers spoke to one of the study’s lead investigators, Dr Yohei Yamauchi, to hear more about their findings.
    • Development of a physiologically relevant lung model for understanding SARS‑CoV-2 infection
      COVID-19 is known to infect the lungs; however, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, Professor Lyle Armstrong and colleagues have been working to develop a human lung epithelium model of SARS-CoV-2 infection and replication. In this article, he describes data that show the model can be successfully infected with SARS‑CoV-2 via angiotensin converting enzyme 2 (ACE2) proteins expressed on the cell surface and allows replication of the virus once inside its cells. The model provides a valuable platform to study SARS‑CoV-2 pathogenesis and evaluate candidate vaccines and therapeutics.
    • Investigating cellular pathways driving severe COVID-19 with proteomics
      Researchers from Massachusetts General Hospital have studied several thousand circulating proteins within the plasma proteome of symptomatic COVID-19 patients and acutely ill non-COVID-19 controls. Nikki Withers discussed their findings and implications of the study with one of the lead authors, Dr Mike Filbin.